Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedApr 07, 2026
DataAggregated Company Financials
Companies55
  • 7D18.0%
  • 3M-6.2%
  • 1Y58.1%
  • YTD-9.6%

Over the last 7 days, the Pharma industry has risen 18%, driven by gains from Curaleaf Holdings of 28%. During this same period, the Quantum BioPharma underperformed, falling 19%. This means that the industry has gained 58% over the past year. Looking forward, earnings are forecast to grow by 49% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 07 Apr 2026CA$14.2bCA$11.4b-CA$1,657,405,027.4412.7x-8.6x1.3x
Thu, 05 Mar 2026CA$14.0bCA$11.2b-CA$1,804,366,150.3813.2x-7.8x1.3x
Sat, 31 Jan 2026CA$14.4bCA$11.2b-CA$1,972,282,610.8916.3x-7.3x1.3x
Mon, 29 Dec 2025CA$16.4bCA$11.2b-CA$1,934,890,119.0616.1x-8.5x1.5x
Wed, 26 Nov 2025CA$13.4bCA$11.4b-CA$1,930,907,058.1214.6x-6.9x1.2x
Fri, 24 Oct 2025CA$15.9bCA$11.3b-CA$2,038,424,469.5732.7x-7.8x1.4x
Sun, 21 Sep 2025CA$16.1bCA$11.2b-CA$2,028,829,168.5239.4x-7.9x1.4x
Tue, 19 Aug 2025CA$15.8bCA$11.8b-CA$2,550,311,028.3836.6x-6.2x1.3x
Thu, 17 Jul 2025CA$10.6bCA$11.7b-CA$2,542,179,845.5519.1x-4.2x0.9x
Sat, 14 Jun 2025CA$9.8bCA$11.6b-CA$2,505,293,273.5318.3x-3.9x0.8x
Mon, 12 May 2025CA$10.0bCA$11.9b-CA$2,536,992,379.8420.8x-3.9x0.8x
Wed, 09 Apr 2025CA$8.9bCA$12.3b-CA$2,623,778,179.5317.4x-3.4x0.7x
Fri, 07 Mar 2025CA$11.5bCA$12.3b-CA$2,637,532,520.8322.2x-4.4x0.9x
Sun, 02 Feb 2025CA$12.0bCA$12.3b-CA$2,397,744,121.5625.9x-5x1x
Tue, 31 Dec 2024CA$12.6bCA$12.1b-CA$2,410,883,218.1024.6x-5.2x1x
Thu, 28 Nov 2024CA$14.3bCA$11.9b-CA$2,565,528,258.8820x-5.6x1.2x
Sat, 26 Oct 2024CA$20.0bCA$11.8b-CA$2,717,171,453.5218.4x-7.4x1.7x
Mon, 23 Sep 2024CA$17.8bCA$11.6b-CA$2,695,385,273.3421.3x-6.6x1.5x
Wed, 21 Aug 2024CA$19.8bCA$11.6b-CA$2,736,003,240.3322.4x-7.3x1.7x
Fri, 19 Jul 2024CA$20.6bCA$11.7b-CA$3,191,938,950.4118.9x-6.5x1.8x
Sun, 16 Jun 2024CA$19.3bCA$11.8b-CA$2,769,898,710.4213.2x-7x1.6x
Tue, 14 May 2024CA$24.6bCA$11.9b-CA$3,392,450,017.1414.2x-7.3x2.1x
Thu, 11 Apr 2024CA$25.6bCA$12.0b-CA$3,493,375,864.239.4x-7.3x2.1x
Sat, 09 Mar 2024CA$19.8bCA$11.9b-CA$3,898,781,168.647.5x-5.1x1.7x
Mon, 05 Feb 2024CA$24.8bCA$12.4b-CA$6,728,600,976.009.1x-3.7x2x
Wed, 03 Jan 2024CA$17.7bCA$12.3b-CA$6,728,092,938.009.3x-2.6x1.4x
Fri, 01 Dec 2023CA$17.9bCA$12.4b-CA$6,775,870,288.008.7x-2.6x1.4x
Sun, 29 Oct 2023CA$14.9bCA$12.5b-CA$7,382,124,790.0011x-2x1.2x
Tue, 26 Sep 2023CA$20.3bCA$12.9b-CA$7,879,381,525.0013.9x-2.6x1.6x
Thu, 24 Aug 2023CA$13.9bCA$13.0b-CA$8,056,604,126.0015.5x-1.7x1.1x
Sat, 22 Jul 2023CA$14.9bCA$13.2b-CA$9,710,742,156.0012.2x-1.5x1.1x
Mon, 19 Jun 2023CA$14.7bCA$13.2b-CA$9,390,780,770.0012.5x-1.6x1.1x
Wed, 17 May 2023CA$14.8bCA$13.3b-CA$10,213,275,744.0010.1x-1.4x1.1x
Fri, 14 Apr 2023CA$15.5bCA$13.2b-CA$9,924,561,603.0010.1x-1.6x1.2x
Price to Earnings Ratio

-1.6x


Total Market Cap: CA$15.5bTotal Earnings: -CA$9,924,561,603.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 4.9% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market3.67%
Healthcare11.41%
Pharma17.95%
Pharma17.95%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TRUL Trulieve CannabisCA$8.337.8%
+CA$115.9m		81.1%PS1x
VRNO Verano HoldingsCA$1.8120.7%
+CA$112.9m		182.8%PS0.6x
CURA Curaleaf HoldingsCA$3.134.3%
+CA$101.7m		203.9%PS1.4x
VREO Vireo GrowthCA$0.551.9%
+CA$60.7m		10.0%PS1.7x
GTII Green Thumb IndustriesCA$9.112.6%
+CA$52.0m		27.4%PE13x

Latest News

CWEB
CA$0.91
Charlotte's Web Holdings
7D
-9.0%
1Y
970.6%
XLY
CA$0.13
Auxly Cannabis Group
7D
-3.8%
1Y
78.6%
GUD
CA$7.65
Knight Therapeutics
7D
3.2%
1Y
36.1%

GUD: Updated 2026 Guidance And Margin Outlook Will Support Bullish Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$0.50, citing updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research points to a more constructive stance on Knight Therapeutics, with bullish analysts adjusting their models to reflect updated views on revenue trajectories, margin sustainability and future P/E assumptions.
VRNO
CA$1.81
Verano Holdings
7D
20.7%
1Y
182.8%

VRNO: Federal Reform Timing Will Drive Repricing As Operations Stay On Track

Analysts have adjusted Verano Holdings' CA$ price target to CA$5, reflecting updated assumptions around modest changes in fair value, discount rate, revenue growth, profit margin, and future P/E based on recent research that cites in-line Q4 results along with ongoing uncertainty around federal reform timing. Analyst Commentary Recent Street commentary around Verano Holdings centers on how updated price targets reflect a balance between in-line quarterly results and persistent uncertainty around federal reform timing.
WEED
CA$1.37
Canopy Growth
7D
3.8%
1Y
17.1%
GTII
CA$9.11
Green Thumb Industries
7D
2.6%
1Y
27.4%
CURA
CA$3.13
Curaleaf Holdings
7D
4.3%
1Y
203.9%

CURA: Domestic Stabilization Efforts Will Support Bullish Re Rating

Analysts now see Curaleaf's fair value drifting slightly higher, even as the average Street price target edges down from CA$6.00 to CA$5.50. They cite recent sales results and efforts to steady the core business while keeping international growth in focus.
QNTM
CA$5.36
Quantum BioPharma
7D
-19.4%
1Y
-37.3%
VREO
CA$0.55
Vireo Growth
7D
1.9%
1Y
10.0%
TRUL
CA$8.33
Trulieve Cannabis
7D
7.8%
1Y
81.1%
GRIN
CA$0.40
Grown Rogue International
7D
-6.0%
1Y
-17.7%
CRON
CA$3.50
Cronos Group
7D
-0.6%
1Y
52.8%
PLTH
CA$0.20
Planet 13 Holdings
7D
-7.1%
1Y
-30.4%
CPH
CA$18.92
Cipher Pharmaceuticals
7D
3.7%
1Y
68.9%

CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution

Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.
CXXI
CA$0.36
C21 Investments
7D
-8.8%
1Y
108.6%
DB
CA$0.13
Decibel Cannabis
7D
-3.7%
1Y
116.7%

Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?

Jan 23
Is Decibel Cannabis (CVE:DB) Using Debt In A Risky Way?